LETTER TO THE EDITOR
COVID-19 and HIV-associated Nephropathies: Double Whammy
Debamita Sutar1, #, Nobendu Mukerjee2, 3, Dattatreya Mukherjee4, Swastika Maitra5, Abhijit Dey6, Athanasios Alexiou4, 5, *, Arabinda Ghosh9, #
Article Information
Identifiers and Pagination:
Year: 2022Volume: 15
E-location ID: e187494452208170
Publisher ID: e187494452208170
DOI: 10.2174/18749445-v15-e2208170
Article History:
Received Date: 3/1/2022Revision Received Date: 31/3/2022
Acceptance Date: 19/5/2022
Electronic publication date: 13/10/2022
Collection year: 2022
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
The number of COVID-19-associated nephropathies (COVAN) rapidly increased before the fourth wave of the COVID-19 pandemic. Similarities and common lesions with the HIV-associated nephropathy (HIVAN) remarkably affect mostly African Americans positive for the APOL1 risk variants; therefore, these cases must be prioritized in new targeted clinical trials.